{"id":424379,"date":"2021-01-29T01:33:17","date_gmt":"2021-01-29T06:33:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=424379"},"modified":"2021-01-29T01:33:17","modified_gmt":"2021-01-29T06:33:17","slug":"nicox-amends-bond-financing-agreement-with-kreos-to-provide-financial-flexibility-in-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nicox-amends-bond-financing-agreement-with-kreos-to-provide-financial-flexibility-in-2021\/","title":{"rendered":"Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021"},"content":{"rendered":"
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Press Release<\/strong>\n <\/td>\n<\/tr>\n
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021<\/td>\n<\/tr>\n
\n \u00a0<\/strong><\/p>\n

January 29, 2021 \u2013 release at 7:30 am CET
Sophia Antipolis, France<\/p>\n

Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital, introducing an additional one-year period of interest-only payments on the outstanding principal starting on February 1, 2021, and an extension of the overall period of the loan by 6 months to July 2024. \u00a0The new one-year interest-only period is expected to provide approximately \u20ac5.5 million of additional flexibility for investment in development activities in 2021.\u00a0 The interest rate of the bonds remains unchanged as a result of this amendment. \u00a0Nicox has granted Kreos Capital 100,000 warrants for 100,000 Nicox shares, equivalent to approximately 0.27% of the present outstanding capital of the Company. <\/p>\n

Michele Garufi, Chairman and Chief Executive Officer of<\/strong> Nicox, <\/strong>said: \u201cAmending this bond financing agreement with Kreos Capital provides Nicox with greater financial flexibility for our exciting advanced development stage product candidates. \u00a0We are now recruiting in four late-stage clinical trials, one of which is conducted by our Chinese partner Ocumension. \u00a0These programs are expected to reach significant milestones in the next 12 to 18 months, including top-line clinical data on our two major assets, NCX 470 and NCX 4251.<\/em>\u201d<\/p>\n

As of February 1, 2021, the outstanding capital under the bond financing agreement with Kreos Capital signed in January 2019 shall be \u20ac16.1 million. \u00a0Under the amendment announced today, the repayment of the outstanding principal will restart on February 1, 2022, and will be completely repaid by July 2024. \u00a0Full details of the bond agreement can be found in the press releases of January 25, 2019 \u2013 http:\/\/www.nicox.com\/assets\/files\/EN-_Kreos-PR_201901.pdf<\/u><\/a> and October 10, 2019 \u2013 https:\/\/www.nicox.com\/assets\/files\/EN_KreosAmendment2_PR_20191010.pdf<\/u><\/a>.<\/p>\n

Nicox also has \u20ac2 million of debt in the form of a credit agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale and LCL, guaranteed by the French State, and granted in August 2020 in the context of the COVID-19 pandemic.<\/p>\n

Warrant Terms<\/strong><\/p>\n

Kreos received 100,000 warrants, each giving a right to subscribe one share in Nicox at an exercise price of \u20ac 4.23 set in accordance with the 7th<\/sup> resolution of the Extraordinary Shareholder Meeting of June 30, 2020.\u00a0 The warrants are exercisable immediately and over a 5-year period. \u00a0No specific restriction applies to the exercise of the warrants. \u00a0The shares obtained by exercise of the warrants will be ordinary shares of Nicox listed on Euronext Paris.<\/p>\n

The exercise of the warrants would not materially dilute existing shareholders.<\/td>\n<\/tr>\n

\n About Nicox<\/strong>\n <\/td>\n<\/tr>\n
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.\u00a0 Nicox\u2019s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.\u00a0 The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.\u00a0 Nicox generates revenue from VYZULTA\u00ae in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE\u2122 in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.\u00a0 <\/p>\n

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. <\/p>\n

For more information on Nicox, its products or pipeline, please visit: www.nicox.com<\/u><\/a>.<\/u><\/td>\n<\/tr>\n

\n About Kreos Capital<\/strong>\n <\/td>\n<\/tr>\n
Kreos Capital is the leading provider of growth-debt financing to high-growth companies in Europe and Israel with revenues up to \u20ac300 million. \u00a0Since 1998, as the pioneer growth debt provider across Europe and Israel, Kreos has completed 540 transactions and committed more than \u20ac2.3 billion in 15 different countries. \u00a0Kreos is dedicated to supporting management teams and their equity investors with flexible loan structures for all stages of a growth company\u2019s development and to address the needs for growth capital, working capital, acquisition financings, lower mid-market buy-outs, roll-up strategies, banks re-financings, as well as pre- and post-IPO financings. \u00a0Kreos\u2019 most recent fund, \u20ac700 million Kreos VI, was launched in January 2019. \u00a0The Kreos global team has extensive debt financing, management, and equity investing experience, covering the markets in Europe and Israel from its locations in London, Tel-Aviv, Berlin and Stockholm.<\/td>\n<\/tr>\n
\n Analyst coverage<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/p>\n

Bryan, Garnier & Co\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Victor Floc\u2019h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Paris, France
Cantor Fitzgerald\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Louise Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.
Edison Investment Research\u00a0\u00a0 Pooya Hemami\u00a0\u00a0\u00a0\u00a0\u00a0 London, UK
H.C. Wainwright & Co\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Yi Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.
Kepler Cheuvreux\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Damien Choplain\u00a0 Paris, France<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. \u00a0Nicox disavows any obligation to correct or to update the information contained in analyst reports.<\/em>\n <\/td>\n<\/tr>\n
\n Contacts<\/strong>\n <\/td>\n<\/tr>\n
\n Nicox<\/strong>
\n
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development\u00a0
T +33 (0)4 97 24 53 00
communications@nicox.com <\/u><\/a><\/td>\n<\/tr>\n
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com<\/u><\/a><\/td>\n		Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com<\/u><\/a><\/td>\n<\/tr>\n
\n Forward-Looking Statements<\/strong>\n <\/td>\n<\/tr>\n
The information contained in this document may be modified without prior notice.\u00a0 This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.\u00a0 These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.\u00a0 Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.<\/p>\n

Risks factors which are likely to have a material effect on Nicox\u2019s business are presented in the 3rd<\/sup> chapter of the \u2018Document d\u2019enregistrement universel, rapport financier annuel et rapport de gestion 2019<\/em>\u2019 filed with the French Autorit\u00e9 des March\u00e9s Financiers<\/em> (AMF) on March 6, 2020 which are available on Nicox\u2019s website (www.nicox.com<\/u><\/a>) and (ii) as restated in the 4th<\/sup> chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox\u2019s website.<\/td>\n<\/tr>\n

\n Nicox S.A.<\/strong>
\n
Drakkar 2
B\u00e2t D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n